BioNTech Reports P-II/III Study Misses First Dual Primary Endpoint for BNT113 in HPV16-Positive Head and Neck Cancer

Shots: BioNTech reported that its P-II/III AHEAD-MERIT study did not meet the first dual 1EP of progression-free survival (PFS) for BNT113 plus pembrolizumab vs pembrolizumab alone in 1L treatment of unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) expressing PD-L1 The Independent Data Monitoring Committee recommended continuing the study to evaluate…

ByPrince Giri3 days ago

NEWS

PDS Biotech Reports Final P-II (VERSATILE-002) Survival Data for PDS0101 + Keytruda in 1L HPV16+ Head & Neck Cancer

Shots: PDS Biotech reported the final topline results from the P-II (VERSATILE-002) Study evaluating safety and efficacy of PDS0101 (Versamune HPV) + Keytruda in 1L R/M HPV16+ HNSCC (n=53) In the Study PDS0101 (SC) with pembrolizumab (IV) for the first 4 cycles, then as a final single dose on cycle 12. Pembrolizumab monotx. was given…

ByPrince GiriAugust 26, 2025

BioNTech Reports P-II/III Study Misses First Dual Primary Endpoint for BNT113 in HPV16-Positive Head and Neck Cancer

PDS Biotech Reports Final P-II (VERSATILE-002) Survival Data for PDS0101 + Keytruda in 1L HPV16+ Head & Neck Cancer

Contact US

FOLLOW US